智通财经APP讯，新锐医药(06108)公布，于2025年8月12日，公司的间接全资附属公司中国新锐、伙伴 A香港新锐万马健康产业有限公司及伙伴B逸恒科技发展香港有限公司订立合作协议，内容有关(其中包 括)对目标公司注资及目标公司事宜的营运及管理。 目标公司从事涉及于中国浙江省嵊州投资及兴建一个健康产业园的项目。项目包括以公开招标方式获得 项目土地的土地使用权，以及在项目土地上兴建、发展及营运相关设施及建筑物。该集团对目标公司的 投资将确认为按公平值计入公司损益的金融资产，其财务业绩将不会与公司的财务业绩综合入账。 于签署合作协议后，伙伴A负责目标公司的营运及管理，目标公司将承担项目的发展、营运及日常管 理。 根据合作协议，目标公司的初始资本为8250万港元(或等值人民币)，伙伴A、中国新锐及伙伴B分别注 资60%、20%及20%。因此，中国新锐将注资1650万港元(或等值人民币)(将以集团内部资源拨付)，而伙 伴A及伙伴B将分别注资4950万港元(或等值人民币)及1650万港元(或等值人民币)。 集团管理层认为，成立承接该项目的目标公司为该集团动用可用资金作出回报、以优质资产扩大投资组 合，以及拓展集团与中 ...

（於百慕達註冊成立之有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 New Ray Medicine International Holding Limited 董 事 會 欣 然 宣 佈，於 二 零 二 五 年 八 月 十 二 日（交 易 時 段 後），本 公 司 的 間 接 全 資 附 屬 公 司 中 國 新 銳、夥 伴A及夥伴B訂 立 合 作 協 議，內 容 有 關（其 中 包 括）對 目 標 公 司 注 資 及 目 標 公 司 事 宜 的 營 運 及 管 理。 （股份代號：6108） 須予披露交易 － 合作協議及成立目標公司 合作協議 目 標 公 司 從 事 涉 及 於 中 國 浙 江 省 嵊 州 投 資 及 興 建 一 個 健 康 產 業 園 的 項 目。 項 目 包 括 以 公 開 招 標 方 式 獲 得 項 ...

智通财经APP讯，新锐医药(06108)公布，于2025年8月6日，卖方(该公司间接全资附属公司)于公开市场 以总代价约1280万港元(不包括交易成本)出售合共80.1万股江西一脉阳光股份。 ...

新锐医药(06108)公布，于2025年8月6日，卖方(该公司间接全资附属公司)于公开市场以总代价约1280万 港元(不包括交易成本)出售合共80.1万股江西一脉阳光股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 New Ray Medicine International Holding Limited （於百慕達註冊成立之有限公司） （股份代號：6108） 須予披露交易 － 出售上市證券 出售事項 於 二 零 二 五 年 八 月 六 日，賣 方（本 公 司 間 接 全 資 附 屬 公 司）於 公 開 市 場 以 總 代 價 約12.8百 萬 港 元（不 包 括 交 易 成 本）出 售 合 共801,000股 江 西 一 脈 陽 光 股 份。 上市規則之涵義 由 於 出 售 事 項 最 高 適 用 百 分 比 率（定 義 見 上 市 規 則）超 過5%但少於25%，故 根 據上市規則第14章，出 售 事 項 構 成 本 公 司 一 項 須 予 披 露 交 易，因 此 須 遵 守 上 市 規 則 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 新銳醫藥國際控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06108 | 說明 | 新銳醫藥 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | 0.05 HKD | | | 150,000,000 | | 增加 / 減少 (-) | | | 12,000,000,000 | | | HKD | | | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.01 HK ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新銳醫藥國際控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06108 | 說明 | 新銳醫藥 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.05 HKD | | 150,000,000 | | 增加 / 減少 (-) | | | 12,000,000,000 | | | HKD | | | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.01 HKD ...

Financial Performance - For the fiscal year ending December 31, 2024, the group recorded revenue of approximately HKD 93.9 million, an increase of about 87.1% compared to HKD 50.2 million in the previous year[7]. - The gross profit for the fiscal year was approximately HKD 11.5 million, a decrease of about 10.9% from HKD 12.9 million in the previous year[7]. - The net loss attributable to the company's owners was approximately HKD 31.0 million, an increase of about 39.6% from a loss of HKD 22.2 million in the previous year[7]. - The board of directors did not recommend the payment of a final dividend for the fiscal year ending December 31, 2024, consistent with the previous year[7]. - Revenue from the distribution and trade of pharmaceuticals and related products increased by approximately 106.8% to HKD 88.7 million, compared to HKD 42.9 million in the previous fiscal year[17]. - Revenue from marketing and promotional services decreased by approximately 28.8% to HKD 5.2 million, down from HKD 7.3 million in the previous fiscal year[18]. - Total revenue for the year was approximately HKD 93.9 million, an increase of about 87.1% compared to approximately HKD 50.2 million in the fiscal year 2023[31]. - Sales cost for the year was approximately HKD 82.5 million, representing an increase of about 121.8% from approximately HKD 37.2 million in the fiscal year 2023[32]. - Other income for the year was approximately HKD 2.1 million, a significant improvement from a loss of approximately HKD 1.3 million in the previous year[34]. - The company reported a net loss of approximately HKD 31.0 million for the year, an increase of about 39.6% compared to the net loss of approximately HKD 22.2 million in the fiscal year 2023[41]. Asset and Investment Overview - The group’s total assets as of December 31, 2024, were approximately HKD 505.2 million, compared to HKD 491.6 million in the previous year[6]. - The fair value loss on investments in Town Health International Medical Group Limited was approximately HKD 9.4 million, with a fair value of HKD 28.8 million as of December 31, 2024[43]. - The company holds 117,602,000 shares of Town Health, representing about 1.74% of its total issued share capital[44]. - The fair value of the company's securities investment in Jiangxi Yimai Sunshine Group Co., Ltd. reached approximately HKD 60.6 million, with an acquisition cost of about HKD 12.0 million[45]. - The investment in Jiangxi Yimai Sunshine Group contributed a fair value gain of approximately HKD 44.9 million during the year[45]. - The fair value of the investment in Jiangxi Yimai Sunshine Group accounted for about 11.3% of the company's total assets[45]. - The company has acquired a 16% stake in China Nüwa Pharmaceutical Group for approximately HKD 17.3 million, with a fair value of HKD 12.9 million as of December 31, 2024[48]. - The investment in Nüwa Pharmaceutical represents about 2.6% of the group's total assets, with a fair value loss of approximately HKD 4.4 million recognized during the year[48]. - Jiangxi Yimai Sunshine Group's investment in Shengzhou New Rui Wanma is valued at approximately HKD 29.9 million, accounting for about 5.9% of total assets[49]. Operational Strategies and Market Conditions - The group has been actively enhancing cooperation with suppliers and end customers to improve sales and marketing capabilities amid market challenges[9]. - The group launched pharmaceutical chemical reagent products in China during 2024, contributing to revenue growth despite initial lower gross margins[9]. - The demand for the group’s second-generation cephalosporin product decreased due to stricter antibiotic management policies in various regions of mainland China[9]. - The group plans to seek new distribution rights for products to enhance its product portfolio and improve long-term sustainable development[21]. - The group aims to enhance its local distribution network and sales and marketing capabilities to strengthen its competitive advantage in China[22]. - The group will focus on reallocating resources to core business development in the distribution and trade of pharmaceuticals and related products in China[23]. - The group anticipates ongoing pressure on drug prices due to national volume-based procurement policies, which may impact future profitability[20]. - The group will continue to monitor national policy guidelines and adapt to market changes to maximize shareholder returns[10]. Governance and Management - The company has a strong management team with over 19 years of experience in the pharmaceutical distribution industry, led by CEO Wang Qiukin[85]. - The board consists of six members, including three executive directors and three independent non-executive directors[146]. - The company has complied with the corporate governance code, except for a deviation regarding the roles of the Chairman and CEO being held by the same person[142]. - The company has established a dividend policy that considers various factors, including cash levels and expected financial performance, without a predetermined dividend payout ratio[138]. - The company has implemented anti-corruption and reporting policies to enhance internal fairness awareness[144]. - The company has established a compensation policy to attract and retain executives, considering market salary levels, individual performance, and work experience[157]. - The nomination committee is responsible for reviewing the board's structure, size, and composition, and for recommending candidates for election at the annual general meeting[159]. - The board is responsible for formulating business strategies and overall policies while monitoring management performance[146]. Environmental, Social, and Governance (ESG) Initiatives - The report covers the company's performance in environmental, social, and governance (ESG) aspects for the year ending December 31, 2024[183]. - The company's carbon footprint for the reporting year was 89.3 tons of CO2 equivalent, an increase of approximately 22.3% compared to 73.0 tons in 2023[194]. - The company has implemented an internal environmental policy to manage and reduce its operational impact on the environment[191]. - The company encourages stakeholder feedback on its environmental, social, and governance policies and performance[189]. - The company has no significant harmful waste due to its operations not involving manufacturing processes[196]. - The company emphasizes efficient use of natural resources, focusing on energy-saving policies related to electricity, water, gasoline, and harmless waste[199]. - The company adopts a prudent approach to resource protection, implementing policies to minimize environmental impact during operations[200].

Financial Performance - For the fiscal year ending December 31, 2024, the group recorded revenue of approximately HKD 93.9 million, an increase of about 87.1% compared to HKD 50.2 million in 2023[2] - The gross profit for the same period was approximately HKD 11.5 million, a decrease of about 10.9% from HKD 12.9 million in 2023[2] - The net loss attributable to the owners of the company was approximately HKD 31.0 million, an increase of about 39.6% from a loss of HKD 22.2 million in 2023[2] - The company reported a basic and diluted loss per share of HKD 1.86 for the year, compared to HKD 1.33 in 2023[3] - The company experienced a fair value gain on financial assets of HKD 3.9 million, compared to HKD 0.4 million in the previous year[3] - The company reported a pre-tax loss of HKD (32,060,000) for the year, compared to a pre-tax loss of HKD (22,342,000) in 2023, indicating a worsening financial performance[11] - The company reported a net loss attributable to shareholders of HKD 31,013,000 in 2024, compared to a loss of HKD 22,170,000 in 2023, indicating a worsening of approximately 39.9%[24] - The net loss for the year was approximately HKD 31.0 million, an increase of about 39.6% compared to approximately HKD 22.2 million in the previous fiscal year[53] Revenue Breakdown - Revenue from the distribution and trade of pharmaceutical and related products was HKD 88,708,000, up from HKD 42,852,000 in the previous year, marking a growth of 106.7%[11] - The marketing and promotion services segment generated revenue of HKD 5,237,000, down from HKD 7,302,000 in the previous year, reflecting a decline of 28.3%[11] - The total revenue for the year ended December 31, 2024, was HKD 93,945,000, a significant increase from HKD 50,154,000 in 2023, representing an increase of 87.2%[7] - Revenue from the pharmaceutical and related products distribution and trade segment was approximately HKD 88.7 million, representing a growth of about 106.8% from approximately HKD 42.9 million in the previous fiscal year[41] Assets and Liabilities - As of December 31, 2024, the group's asset-to-liability ratio was zero, unchanged from 2023[2] - The total assets decreased slightly from HKD 477.9 million in 2023 to HKD 486.0 million in 2024[4] - Trade and other payables decreased significantly from HKD 26.2 million in 2023 to HKD 5.3 million in 2024[4] - Trade receivables increased to HKD 104,704,000 in 2024 from HKD 94,399,000 in 2023, representing an increase of about 10.5%[25] - The company's equity as of December 31, 2024, is approximately HKD 471.0 million, down from HKD 480.3 million in 2023[79] Dividends - The board of directors does not recommend the payment of a final dividend for the year ending December 31, 2024[2] - The company did not declare or recommend any dividends for the years ending December 31, 2024, and December 31, 2023[23] - The Board does not recommend the payment of a final dividend for the current year[93] Impairment and Expenses - The total impairment loss on trade and other receivables was HKD (5,712,000), with inventory impairment loss amounting to HKD (13,114,000) for the year ended December 31, 2024[11] - The impairment loss on trade and other receivables increased to HKD 5,712,000 in 2024 from HKD 4,067,000 in 2023, an increase of approximately 40.4%[22] - Administrative expenses were approximately HKD 14.7 million, a slight increase of about 0.7% from approximately HKD 14.6 million in the previous fiscal year[48] - Total employee costs rose to HKD 8,719,000 in 2024 from HKD 8,063,000 in 2023, an increase of about 8.1%[22] Investments - The fair value of the investment in Town Health International Medical Group Limited is approximately HKD 28.8 million, representing about 5.7% of the group's total assets as of December 31, 2024[55] - The group confirmed a fair value gain of approximately HKD 44.9 million from its investment in Jiangxi Yimai Sunshine Group during the year[58] - The group purchased 16% of the issued share capital of China Nüwa Pharmaceutical Group Co., Ltd. for approximately HKD 17.3 million[59] - The fair value of the investment in the target company is approximately HKD 12.9 million, with a fair value loss of about HKD 4.4 million confirmed during the year[59] - The group holds approximately 39% equity in Shengzhou New Sharp Wanma, with a fair value of about HKD 29.9 million, representing approximately 5.9% of the group's total assets as of December 31, 2024[61] Legal and Governance - The company is involved in a legal case initiated by the Securities and Futures Commission (SFC) regarding actions taken by two former directors, with a court hearing scheduled for May 11, 2021[82] - The SFC claims that the first and second defendants are responsible for illegal activities that resulted in a loss of information to company members, with a specific claim for HKD 26 million plus interest against the first defendant[83] - A court ruling on September 13, 2024, ordered the SFC to pay 75% of the legal costs incurred by the company, while the first and second defendants are responsible for 25%[86] - The ongoing appeal by the SFC seeks to overturn certain court decisions related to the case[87] - The company has established a Corporate Governance Committee to formulate and review corporate governance policies and practices[90] - The CEO, Ms. Wang Qiuqin, also serves as the Chairman of the Board, which constitutes a deviation from the corporate governance code[91] Future Outlook - The group plans to enhance its product portfolio by seeking distribution rights for new products and improving marketing strategies by 2025[36] - The group aims to strengthen its local distribution network and sales capabilities to enhance competitive advantages in China[37] - The group intends to focus on long-term growth by reallocating resources to core business areas and seeking potential acquisition opportunities[38] - The group anticipates ongoing price pressure on pharmaceutical products due to the continuation of national volume-based procurement policies[35]

Financial Performance - For the six months ended June 30, 2024, the group recorded revenue of approximately HKD 16,718,000, a decrease of about 46.1% compared to HKD 31,016,000 for the same period in 2023[1]. - The net loss attributable to the owners of the company for the six months ended June 30, 2024, was approximately HKD 4,088,000, a reduction of about 69.4% from HKD 13,357,000 in the same period of 2023[2]. - Total comprehensive expenses for the period amounted to HKD 15,052,000, down from HKD 31,276,000 in the same period of 2023[2]. - Basic and diluted loss per share for the period was HKD 0.24, compared to HKD 0.80 for the same period in 2023[2]. - The group reported a net loss before tax of HKD 4,083,000 for the six months ended June 30, 2024, compared to a net loss of HKD 13,357,000 for the same period in 2023[10][14]. - The loss for the period was approximately HKD 4,088,000, a decrease from a loss of approximately HKD 13,357,000 for the same period in 2023[46]. Revenue Breakdown - For the six months ended June 30, 2024, the total revenue was HKD 16,718,000, with HKD 12,116,000 from pharmaceutical product distribution and trading, and HKD 4,602,000 from marketing and promotion services[9]. - Revenue from the pharmaceutical product distribution and trading segment was HKD 12,116,000, down approximately 55.3% from HKD 27,124,000 in the same period last year[31]. - Revenue from marketing and promotion services increased by approximately 18.2% to HKD 4,602,000, compared to HKD 3,892,000 in the same period last year[32]. Assets and Liabilities - As of June 30, 2024, the group's asset-to-liability ratio was zero, unchanged from December 31, 2023[1]. - Non-current assets as of June 30, 2024, totaled HKD 121,608,000, an increase from HKD 113,407,000 as of December 31, 2023[3]. - Current assets amounted to HKD 373,616,000 as of June 30, 2024, slightly down from HKD 378,196,000 as of December 31, 2023[3]. - The company's total liabilities as of June 30, 2024, were HKD 5,759,000, consistent with HKD 5,795,000 as of December 31, 2023[3]. - The equity attributable to the owners of the company was HKD 468,671,000 as of June 30, 2024, down from HKD 480,253,000 as of December 31, 2023[3]. Expenses - The group incurred administrative expenses of HKD 5,867,000 and selling and distribution expenses of HKD 4,876,000 during the same period[9]. - Selling and distribution expenses were approximately HKD 4,876,000, a decrease of about 35.4% from approximately HKD 7,552,000 for the six months ended June 30, 2023[43]. - Administrative expenses were approximately HKD 5,867,000, a slight increase of about 0.9% compared to approximately HKD 5,814,000 for the six months ended June 30, 2023[44]. Investments and Acquisitions - The group acquired properties, plants, and equipment amounting to approximately HKD 567,000,000 during the period, compared to HKD 43,000,000 for the six months ended June 30, 2023[17]. - The group acquired 16% of the issued share capital of China Nüwa Pharmaceutical Group Co., Ltd. for HKD 17,280,000 on May 16, 2024[48]. - The investment in China Nüwa Pharmaceutical is classified as a financial asset measured at fair value through other comprehensive income, reflecting a long-term investment strategy[48]. - The group has invested approximately HKD 14,529,000 in Shengzhou New Sharp Wanlin during the reporting period[59]. Legal and Governance - The group is involved in a legal case initiated by the Securities and Futures Commission regarding past directors' responsibilities, with a claim for HKD 26 million plus interest[63][64]. - The company has adopted its own corporate governance code in accordance with the principles and rules set out in the Corporate Governance Code under Appendix C1 of the Listing Rules[66]. - The company has confirmed that all directors have complied with the required standards of the standard code for securities transactions during the period[67]. - There are no significant litigations, arbitrations, or claims involving any member of the group as of June 30, 2024, and no unresolved or potential significant litigations are anticipated[65]. Market and Operational Insights - The group faced a decline in demand for its second-generation cephalosporin products due to the implementation of stricter antibiotic management policies in mainland China[27]. - The group operates a network of customers across various regions in China, including Zhejiang, Jiangsu, Hainan, Hunan, and Guangdong provinces[26]. - The group continues to monitor macroeconomic changes and trends in the healthcare industry to balance growth and risk[56]. - The group has not made any significant investments, acquisitions, or disposals during the reporting period[51]. Employee and Operational Metrics - Employee costs for the period amounted to approximately HKD 4,022,000, compared to HKD 3,843,000 for the six months ended June 30, 2023[61]. - The group has 23 employees as of June 30, 2024, unchanged from December 31, 2023[61]. Currency and Risk Management - The group faces foreign currency risk due to operations in China, with most transactions denominated in RMB[62]. - The group does not consider the potential impact of exchange rate fluctuations on its profit and loss to be significant, thus no foreign currency hedging policy is adopted[62].